699 reports of this reaction
3.5% of all ASENAPINE MALEATE reports
#2 most reported adverse reaction
SEDATION is the #2 most commonly reported adverse reaction for ASENAPINE MALEATE, manufactured by Allergan, Inc.. There are 699 FDA adverse event reports linking ASENAPINE MALEATE to SEDATION. This represents approximately 3.5% of all 20,068 adverse event reports for this drug.
Patients taking ASENAPINE MALEATE who experience sedation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEDATION is moderately reported among ASENAPINE MALEATE users, representing a notable but not dominant share of adverse events.
In addition to sedation, the following adverse reactions have been reported for ASENAPINE MALEATE:
The following drugs have also been linked to sedation in FDA adverse event reports:
SEDATION has been reported as an adverse event in 699 FDA reports for ASENAPINE MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEDATION accounts for approximately 3.5% of all adverse event reports for ASENAPINE MALEATE, making it one of the most commonly reported side effect.
If you experience sedation while taking ASENAPINE MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.